510(k) · Cleared
ClearedLifesign Cocaine, Marijuana (THC), Lifesign DOA2 (THC/Coc), Status Stik THC/Coc, Accusign Stik THC/Coc, Accustik THC/Coc
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Princeton BioMeditech Corp. · DIO Enzyme Immunoassay, Cocaine And Cocaine Metabolites
Cleared on Jun 10, 2002 as substantially equivalent to K990786 (Princeton BioMeditech Corp., 1999) after a 182-day review. Its family tree reaches back 1 generation to 1999.
- Decided
- Jun 10, 2002
- Review
- 182 days
- Class
- Class II
- Product code
- DIO
- Recalls
- None
- Predicates
- 1
Its longest line of descent runs back 1 generation to K990786 (1999). No later device cites it as a predicate yet.
- Root · 1 generation backK990786 Accusign Doa 10, Accusign Doa 10 Panel, Acusign…Princeton BioMeditech Corp. · 1999
- This deviceK014067 Lifesign Cocaine, Marijuana (THC), Lifesign DOA2 (THC/Coc), Status…Princeton BioMeditech Corp. · 2002
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −1 | K990786 | Accusign Doa 10, Accusign Doa 10 Panel, Acusign… | Princeton BioMeditech Corp. | 1999 | — |
| 0 (this device) | K014067 | Lifesign Cocaine, Marijuana (THC), Lifesign DOA2 (THC/Coc), Status Stik… | Princeton BioMeditech Corp. | 2002 | — |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in DIO? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new DIO device
- #1 K213211 Carolina Liquid Chemistries Cocaine and…score 3.0 · 2 generations · no Class I recall
- #2 Held for the reportin the report
- #3 Held for the reportin the report
What was it cleared against? (1)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K990786 | Accusign Doa 10, Accusign Doa 10 Panel, Acusign Met/Opi/Coc/THC/PCP/Bzo/Bar/MTD/Tca/Amp…Summary page 1…ems, Toxicology (91DKE, 91DIO for Enzyme Immunoassay) 4. Identification of legally marketed device to which claims equivalence: k990786; Status D.S T M DOAl O(MET/OPI/COC/THC/PCP/BZO/BAR/MTD/TCA/AMP) - 5. Device Description: Lifesign@Home Drug Test (THCK… | 1999 |
What descends from it?
No later submission names this one as a predicate yet.
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- Its one ancestor has no recall.
- 4 other devices also cite its predicate K990786.
How does its category compare?
All DIO devicesDIO Enzyme Immunoassay, Cocaine And Cocaine Metabolites: FDA decisions, review times, recalls and adverse event reports over 20 years.
FDA decisions per year · DIO
1in 2022
2026 to Oct 25, outlined.
Median 510(k) review, days · DIO
267in 2017
Receipt to decision; years with fewer than 3 clearances left blank.
Recalls per year · DIO
1in 2013
Class I (0 since 2007) Class II/III not classified
Adverse event reports per year · DIO
1in 2023
MAUDE reports naming product code DIO, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 0 | — | 0 | 0 |
| 2008 | 0 | — | 0 | 0 |
| 2009 | 1 | — | 0 | 0 |
| 2010 | 0 | — | 0 | 0 |
| 2011 | 5 | 65 | 0 | 4 |
| 2012 | 5 | 139 | 0 | 0 |
| 2013 | 2 | — | 1 | 0 |
| 2014 | 2 | — | 0 | 1 |
| 2015 | 2 | — | 0 | 7 |
| 2016 | 3 | 88 | 0 | 9 |
| 2017 | 3 | 267 | 0 | 16 |
| 2018 | 1 | — | 0 | 12 |
| 2019 | 0 | — | 0 | 22 |
| 2020 | 1 | — | 0 | 0 |
| 2021 | 1 | — | 0 | 0 |
| 2022 | 1 | — | 0 | 1 |
| 2023 | 0 | — | 0 | 1 |
| 2024 | 0 | — | 0 | 0 |
| 2025 | 0 | — | 0 | 0 |
| 2026 | 0 | — | 0 | — |
What is it indicated for?
Immunoassay for the qualitative detection of THC metabolite, 11-nor-A9-THC-9-carboxylic acid, at the cut-off of 50 ng/mL and cocaine metabolite, benzoylecgonine, at the cut-off of 300 ng/mL in urine to assist in screening of drugs of abuse samples at home. For In vitro Diagnostic Use
Immunoassay for the qualitative detection of THC metabolite, 11-nor-A’-THC-9-carboxylic acid, at the cut-off of 50 ng/mL and cocaine metabolite, benzoylecgonine, at the cut-off of 300 ng/mL in urine to assist in screening of drugs of abuse samples. For In vitro Diagnostic Use
Indications for use as stated in the FDA summary.
https://510kreport.com/device/K014067 · printed Nov 6, 2026
Cite this page
510(k) Report. “K014067: Lifesign Cocaine, Marijuana (THC), Lifesign DOA2 (THC/Coc), Status Stik THC/Coc, Accusign Stik THC/Coc, Accustik THC/Coc.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K014067
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 30, 2026 (extraction version 2d9447fa9ea4)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026